| scholarly article | Q13442814 |
| P356 | DOI | 10.1111/J.1468-1331.2012.03766.X |
| P698 | PubMed publication ID | 22650322 |
| P2093 | author name string | D Ferrari | |
| A F Carpentier | |||
| C Belin | |||
| R Ursu | |||
| C Levy | |||
| O Bailon | |||
| A-L Dubessy | |||
| C Banissi | |||
| P2860 | cites work | Boswellia serrata acts on cerebral edema in patients irradiated for brain tumors: a prospective, randomized, placebo-controlled, double-blind pilot trial. | Q53052123 |
| Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. | Q55472252 | ||
| Mechanism of dexamethasone suppression of brain tumor-associated vascular permeability in rats. Involvement of the glucocorticoid receptor and vascular permeability factor | Q24561970 | ||
| Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma | Q27860910 | ||
| AT1 receptor is present in glioma cells; its blockage reduces the growth of rat glioma | Q28365043 | ||
| Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma | Q29617568 | ||
| Primary brain tumours in adults. | Q30765293 | ||
| Do inhibitors of angiotensin-I-converting enzyme protect against risk of cancer? | Q34749837 | ||
| Blood-brain barrier breakdown in septic encephalopathy and brain tumours | Q34774036 | ||
| The use and toxicity of steroids in the management of patients with brain metastases. | Q37078927 | ||
| Dexamethasone treatment in patients with brain metastases and primary brain tumors: do the benefits outweigh the side-effects? | Q39406644 | ||
| Functional expression of the angiotensin II type 1 receptor in human ovarian carcinoma cells and its blockade therapy resulting in suppression of tumor invasion, angiogenesis, and peritoneal dissemination | Q40438044 | ||
| Dexamethasone decreases temozolomide-induced apoptosis in human gliobastoma T98G cells. | Q40463014 | ||
| A selective and oral small molecule inhibitor of vascular epithelial growth factor receptor (VEGFR)-2 and VEGFR-1 inhibits neovascularization and vascular permeability | Q42801432 | ||
| Steroid requirements during radiotherapy for malignant gliomas | Q43148724 | ||
| Blockade of angiotensin AT1a receptor signaling reduces tumor growth, angiogenesis, and metastasis | Q44018962 | ||
| Angiotensin-converting enzyme inhibitors and the risk of cancer: a population-based cohort study in Denmark. | Q50569886 | ||
| P433 | issue | 10 | |
| P921 | main subject | glioblastoma | Q282142 |
| P304 | page(s) | 1337-1342 | |
| P577 | publication date | 2012-05-31 | |
| P1433 | published in | European Journal of Neurology | Q15757256 |
| P1476 | title | Steroid-sparing effects of angiotensin-II inhibitors in glioblastoma patients | |
| P478 | volume | 19 |
| Q26851160 | A conceptually new treatment approach for relapsed glioblastoma: coordinated undermining of survival paths with nine repurposed drugs (CUSP9) by the International Initiative for Accelerated Improvement of Glioblastoma Care |
| Q42282790 | Angiotensinogen and HLA class II predict bevacizumab response in recurrent glioblastoma patients |
| Q58085056 | Angiotensinogen rs5050 germline genetic variant as potential biomarker of poor prognosis in astrocytoma |
| Q34437996 | CUSP9* treatment protocol for recurrent glioblastoma: aprepitant, artesunate, auranofin, captopril, celecoxib, disulfiram, itraconazole, ritonavir, sertraline augmenting continuous low dose temozolomide |
| Q88775005 | Corticosteroid use endpoints in neuro-oncology: Response Assessment in Neuro-Oncology Working Group |
| Q38718044 | Effect of angiotensin system inhibitors on survival in newly diagnosed glioma patients and recurrent glioblastoma patients receiving chemotherapy and/or bevacizumab |
| Q90926971 | Glioblastoma Therapy in the Age of Molecular Medicine |
| Q36320980 | Hypofractionated Radiotherapy and Stereotactic Boost with Concurrent and Adjuvant Temozolamide for Glioblastoma in Good Performance Status Elderly Patients - Early Results of a Phase II Trial |
| Q49015944 | Impact of Angiotensin-II receptor blockers on vasogenic edema in glioblastoma patients |
| Q41686732 | Impact of renin-angiotensin system blockade on clinical outcome in glioblastoma |
| Q46040914 | Progress in European neurology 2012-2013. |
| Q49947511 | Renin angiotensin system and its role in biomarkers and treatment in gliomas |
| Q88248824 | Renin-Angiotensin System Inhibitors to Mitigate Cancer Treatment-Related Adverse Events |
| Q92446824 | Repurposing existing agents as adjunct therapies for glioblastoma |
| Q38587724 | Repurposing some older drugs that cross the blood-brain barrier and have potential anticancer activity to provide new treatment options for glioblastoma |
| Q47863448 | Targeting the renin-angiotensin system to improve cancer treatment: Implications for immunotherapy. |
| Q93382199 | The renin angiotensin system (RAS) mediates bifunctional growth regulation in melanoma and is a novel target for therapeutic intervention |
| Q35388346 | Transcriptional network analysis reveals that AT1 and AT2 angiotensin II receptors are both involved in the regulation of genes essential for glioma progression. |
| Q38154959 | Tumor-associated edema in brain cancer patients: pathogenesis and management |